Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates

Key Points

• Lexeo Therapeutics matched earnings expectations, reporting a quarterly loss of $0.30 per share, in line with analysts’ consensus estimate.
• Shares rose 4.6% to $5.00, though the stock remains well below its 12-month high of $10.99. Analysts maintain an overall “Buy” rating with an average price target of $18.75.
• Institutional investors own 60.67% of the company, while insiders recently sold shares primarily to cover tax obligations related to vested equity awards.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.30), FiscalAI reports.

Lexeo Therapeutics Stock Up 4.6%

NASDAQ:LXEO traded up $0.22 on Wednesday, reaching $5.00. The company's stock had a trading volume of 877,513 shares, compared to its average volume of 950,138. Lexeo Therapeutics has a 12-month low of $3.99 and a 12-month high of $10.99. The stock has a 50 day moving average price of $4.63 and a 200 day moving average price of $5.67. The firm has a market cap of $392.61 million, a price-to-earnings ratio of -3.45 and a beta of 1.46.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wall Street Zen upgraded Lexeo Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Weiss Ratings cut Lexeo Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, July 30th. Chardan Capital raised Lexeo Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Finally, JPMorgan Chase & Co. dropped their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $18.75.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the transaction, the insider owned 82,194 shares of the company's stock, valued at $363,297.48. This trade represents a 21.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the sale, the chief executive officer owned 377,817 shares of the company's stock, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 62,204 shares of company stock valued at $280,089 over the last three months. Corporate insiders own 2.00% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LXEO. RA Capital Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at $49,650,000. Paradigm Biocapital Advisors LP purchased a new position in Lexeo Therapeutics during the 4th quarter valued at about $47,299,000. Vestal Point Capital LP boosted its holdings in Lexeo Therapeutics by 37.7% during the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company's stock valued at $44,437,000 after acquiring an additional 1,225,000 shares during the period. Balyasny Asset Management L.P. acquired a new position in Lexeo Therapeutics in the 2nd quarter valued at about $16,117,000. Finally, Citadel Advisors LLC increased its stake in Lexeo Therapeutics by 3.1% during the third quarter. Citadel Advisors LLC now owns 3,719,043 shares of the company's stock worth $24,694,000 after purchasing an additional 111,076 shares during the period. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source